BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29537847)

  • 1. Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.
    Horton JR; Liu X; Wu L; Zhang K; Shanks J; Zhang X; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Pohida K; Fang Y; Hu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Yan Q; Cheng X
    J Med Chem; 2018 Apr; 61(7):3193-3208. PubMed ID: 29537847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
    Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
    J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
    Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
    Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS
    J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of KDM5A for cancer treatment.
    Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
    Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
    Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
    Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potent, selective KDM5 inhibitors.
    Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
    Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
    Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analogs of the dihydroceramide desaturase inhibitor GT11 modified at the amide function: synthesis and biological activities.
    Bedia C; Triola G; Casas J; Llebaria A; Fabriàs G
    Org Biomol Chem; 2005 Oct; 3(20):3707-12. PubMed ID: 16211106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
    J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of KDM5A in human cancer.
    Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
    J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of ryuvidine as a KDM5A inhibitor.
    Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
    Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
    Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
    Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
    Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
    J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
    Wu F; Zhou C; Yao Y; Wei L; Feng Z; Deng L; Song Y
    J Med Chem; 2016 Jan; 59(1):253-263. PubMed ID: 26652247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
    Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
    Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
    Dai Y; Guo Y; Guo J; Pease LJ; Li J; Marcotte PA; Glaser KB; Tapang P; Albert DH; Richardson PL; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1897-901. PubMed ID: 12749893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.